1. Cornu JN, Ahyai S, Bachmann A, de la Rosette J, Gilling P, Gratzke C, McVary K, Novara G, Woo H, Madersbacher S. A systematic review and meta-analysis of functional outcomes and complications following transurethral procedures for lower urinary tract symptoms resulting from benign prostatic obstruction: an update. Eur Urol. 2015; 67:1066–1096.
2. Pyo JS, Cho WJ. Systematic review and meta-analysis of prostatic artery embolisation for lower urinary tract symptoms related to benign prostatic hyperplasia. Clin Radiol. 2017; 72:16–22.
3. Aaron L, Franco OE, Hayward SW. Review of prostate anatomy and embryology and the etiology of benign prostatic hyperplasia. Urol Clin North Am. 2016; 43:279–288.
4. Strand DW, Costa DN, Francis F, Ricke WA, Roehrborn CG. Targeting phenotypic heterogeneity in benign prostatic hyperplasia. Differentiation. 2017; 96:49–61.
5. Vignozzi L, Rastrelli G, Corona G, Gacci M, Forti G, Maggi M. Benign prostatic hyperplasia: a new metabolic disease? J Endocrinol Invest. 2014; 37:313–322.
6. Steers WD. 5alpha-reductase activity in the prostate. Urology. 2001; 58:17–24.
7. Nicholson TM, Ricke WA. Androgens and estrogens in benign prostatic hyperplasia: past, present and future. Differentiation. 2011; 82:184–199.
8. Andriole G, Bruchovsky N, Chung LW, Matsumoto AM, Rittmaster R, Roehrborn C, Russell D, Tindall D. Dihydrotestosterone and the prostate: the scientific rationale for 5alpha-reductase inhibitors in the treatment of benign prostatic hyperplasia. J Urol. 2004; 172:1399–1403.
9. Azzouni F, Mohler J. Role of 5α-reductase inhibitors in benign prostatic diseases. Prostate Cancer Prostatic Dis. 2012; 15:222–230.
10. Gharaee-Kermani M, Macoska JA. Promising molecular targets and biomarkers for male BPH and LUTS. Curr Urol Rep. 2013; 14:628–637.
11. Ho CK, Habib FK. Estrogen and androgen signaling in the pathogenesis of BPH. Nat Rev Urol. 2011; 8:29–41.
12. Thorner DA, Weiss JP. Benign prostatic hyperplasia: symptoms, symptom scores, and outcome measures. Urol Clin North Am. 2009; 36:417–429.
13. Smith RD, Patel A. Transurethral resection of the prostate revisited and updated. Curr Opin Urol. 2011; 21:36–41.
14. Traish AM, Melcangi RC, Bortolato M, Garcia-Segura LM, Zitzmann M. Adverse effects of 5α-reductase inhibitors: what do we know, don't know, and need to know? Rev Endocr Metab Disord. 2015; 16:177–198.
15. Lepor H. Alpha-blockers for the treatment of benign prostatic hyperplasia. Urol Clin North Am. 2016; 43:311–323.
16. Chang JS, Chiang LC, Hsu FF, Lin CC. Chemoprevention against hepatocellular carcinoma of
Cornus officinalis in vitro. Am J Chin Med. 2004; 32:717–725.
17. Kang DG, Moon MK, Lee AS, Kwon TO, Kim JS, Lee HS. Cornuside suppresses cytokine-induced proinflammatory and adhesion molecules in the human umbilical vein endothelial cells. Biol Pharm Bull. 2007; 30:1796–1799.
18. Jiang WL, Chen XG, Zhu HB, Hou J, Tian JW. Cornuside attenuates apoptosis and ameliorates mitochondrial energy metabolism in rat cortical neurons. Pharmacology. 2009; 84:162–170.
19. Jeong EJ, Kim TB, Yang H, Kang SY, Kim SY, Sung SH, Kim YC. Neuroprotective iridoid glycosides from
Cornus officinalis fruits against glutamate-induced toxicity in HT22 hippocampal cells. Phytomedicine. 2012; 19:317–321.
20. Telang NT, Li G, Sepkovic DW, Bradlow HL, Wong GY. Antiproliferative effects of Chinese herb Cornus officinalis in a cell culture model for estrogen receptor-positive clinical breast cancer. Mol Med Rep. 2012; 5:22–28.
21. Zhang QC, Zhao Y, Bian HM. Antiplatelet activity of a novel formula composed of malic acid, succinic acid and citric acid from
Cornus officinalis fruit. Phytother Res. 2013; 27:1894–1896.
22. Sun X, Kong L, Zhou L. Protective effect of Fructus corni polysaccharide on hippocampal tissues and its relevant mechanism in epileptic rats induced by lithium chloride-pilocarpine. Exp Ther Med. 2018; 16:445–451.
23. Hwang KA, Hwang YJ, Song J. Antioxidant activities and oxidative stress inhibitory effects of ethanol extracts from
Cornus officinalis on raw 264.7 cells. BMC Complement Altern Med. 2016; 16:196.
24. Park JY, Han AR, Kil YS, Kang U, Kim SH, Nam SJ, Seo EK. A new secoiridoid glycoside from the fruits of
Cornus officinalis (Cornaceae). Nat Prod Res. 2016; 30:1504–1510.
25. Yoon JH, Youn K, Ho CT, Karwe MV, Jeong WS, Jun M. p-Coumaric acid and ursolic acid from
Corni fructus attenuated β-amyloid(25-35)-induced toxicity through regulation of the NF-κB signaling pathway in PC12 cells. J Agric Food Chem. 2014; 62:4911–4916.
26. Ma W, Wang KJ, Cheng CS, Yan GQ, Lu WL, Ge JF, Cheng YX, Li N. Bioactive compounds from
Cornus officinalis fruits and their effects on diabetic nephropathy. J Ethnopharmacol. 2014; 153:840–845.
27. Minciullo PL, Inferrera A, Navarra M, Calapai G, Magno C, Gangemi S. Oxidative stress in benign prostatic hyperplasia: a systematic review. Urol Int. 2015; 94:249–254.
28. Bostanci Y, Kazzazi A, Momtahen S, Laze J, Djavan B. Correlation between benign prostatic hyperplasia and inflammation. Curr Opin Urol. 2013; 23:5–10.
29. Keam SJ, Scott LJ. Dutasteride: a review of its use in the management of prostate disorders. Drugs. 2008; 68:463–485.
30. Traish AM. 5α-reductases in human physiology: an unfolding story. Endocr Pract. 2012; 18:965–975.
31. Pihlajamaa P, Sahu B, Jänne OA. Determinants of receptor- and tissue-specific actions in androgen signaling. Endocr Rev. 2015; 36:357–384.
32. Robins DM. Androgen receptor and molecular mechanisms of male-specific gene expression. Novartis Found Symp. 2005; 268:42–52.
33. Prins GS. Molecular biology of the androgen receptor. Mayo Clin Proc. 2000; 75:Suppl. S32–S35.
34. Watanabe M, Yamada Y, Kato H, Imai H, Nakano H, Araki T, Shiraishi T. Malignant phyllodes tumor of the prostate: retrospective review of specimens obtained by sequential transurethral resection. Pathol Int. 2002; 52:777–783.
35. Cunha GR, Wang YZ, Hayward SW, Risbridger GP. Estrogenic effects on prostatic differentiation and carcinogenesis. Reprod Fertil Dev. 2001; 13:285–296.
36. Huang J, Zhang Y, Dong L, Gao Q, Yin L, Quan H, Chen R, Fu X, Lin D. Ethnopharmacology, phytochemistry, and pharmacology of
Cornus officinalis Sieb. et Zucc. J Ethnopharmacol. 2018; 213:280–301.
37. Park CH, Noh JS, Park JC, Yokozawa T. Beneficial effect of 7-O-galloyl-D-sedoheptulose, a polyphenol isolated from Corni fructus, against diabetes-induced alterations in kidney and adipose tissue of type 2 diabetic db/db mice. Evid Based Complement Alternat Med. 2013; 2013:736856.
38. Vareed SK, Schutzki RE, Nair MG. Lipid peroxidation, cyclooxygenase enzyme and tumor cell proliferation inhibitory compounds in
Cornus kousa fruits. Phytomedicine. 2007; 14:706–709.
39. Wang W, Sun F, An Y, Ai H, Zhang L, Huang W, Li L. Morroniside protects human neuroblastoma SH-SY5Y cells against hydrogen peroxide-induced cytotoxicity. Eur J Pharmacol. 2009; 613:19–23.
40. Xu H, Shen J, Liu H, Shi Y, Li L, Wei M. Morroniside and loganin extracted from
Cornus officinalis have protective effects on rat mesangial cell proliferation exposed to advanced glycation end products by preventing oxidative stress. Can J Physiol Pharmacol. 2006; 84:1267–1273.
41. Xu YD, Cui C, Sun MF, Zhu YL, Chu M, Shi YW, Lin SL, Yang XS, Shen YQ. Neuroprotective effects of loganin on MPTP-induced Parkinson's disease mice: neurochemistry, glial reaction and autophagy studies. J Cell Biochem. 2017; 118:3495–3510.